AI Article Synopsis
- Recent advancements in treating myeloid malignancies have introduced new drugs targeting essential molecular pathways for leukemia cell survival.
- Venetoclax, an effective pro-apoptotic drug, has shown significant success in treating acute myeloid leukemia (AML), prompting further exploration of apoptosis-targeting methods in other myeloid conditions.
- The paper will discuss apoptotic mechanisms, current and emerging therapies for myeloid neoplasia, and highlight key research needs for future developments.
Article Abstract
In recent years, the therapeutic landscape of myeloid malignancies has been completely revolutionized by the introduction of several new drugs, targeting molecular alterations or pathways crucial for leukemia cells survival. Particularly, many agents targeting apoptosis have been investigated in both pre-clinical and clinical studies. For instance, venetoclax, a pro-apoptotic agent active on BCL-2 signaling, has been successfully used in the treatment of acute myeloid leukemia (AML). The impressive results achieved in this context have made the apoptotic pathway an attractive target also in other myeloid neoplasms, translating the experience of AML. Therefore, several drugs are now under investigation either as single or in combination strategies, due to their synergistic efficacy and capacity to overcome resistance. In this paper, we will review the mechanisms of apoptosis and the specific drugs currently used and under investigation for the treatment of myeloid neoplasia, identifying critical research necessities for the upcoming years.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.blre.2023.101130 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!